A five-minute weekly dose of peanut protein through the skin, delivered by a novel microneedle technology, was superior in desensitizing peanut-allergic mice compared to administering the protein through a skin patch, a new study has found.  Click for more details.

Moonlight Therapeutics, Inc., announced today it has completed a pre-Investigational New Drug Application (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathway for the development of MOON101 for the treatment of peanut allergy.  Click for more details.

Moonlight Therapeutics, Inc., announced today funding from a Phase 2 Small Business grant from the National Institute of Allergy and Infectious Diseases (NIAID) to support the company’s preclinical development of a targeted peanut allergy treatment  Click for more details.

Moonlight Therapeutics, Inc., announced today an investment of over $300,000 from a small group of private investors. Moonlight Therapeutics is a biotechnology company developing treatments for food allergies and its lead program focuses on a treatment for peanut allergies.  Click for more details.

Moonlight Therapeutics, Inc., a biotechnology company developing treatments for food allergies, announced today the receipt of $2.5 million in funding for preclinical studies and product development that will enable preparations for a clinical trial for its lead program in peanut allergy. This funding was awarded through a highly competitive Small Business Technology Transfer (STTR) Fast Track grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).  Click for more details.

Moonlight Therapeutics Inc will give a corporate presentation at Biotech Showcase 2018, an independent investor conference for public and private life sciences companies.

The Advanced Technology Development Center (ATDC) at Georgia Tech is Georgia’s technology incubator. Founded in 1980, ATDC has developed a global reputation for fostering technological entrepreneurship. Forbes named ATDC to its list of “Incubators Changing the World” in 2010 and 2013, alongside Y Combinator and the Palo Alto Research Center.

Moonlight Therapeutics is selected to present at Southeast BIO (SEBIO) Investor Forum